BB Biotech Ventures

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health through the development of controlled metabolic accelerators (CMAs). These innovative therapeutics are designed to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. By addressing the underlying metabolic risk factors associated with cardiovascular mortality and morbidity, Rivus aims to provide effective oral small-molecule treatments for patients suffering from these conditions.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Abyrx, Inc. is a medical device company based in Irvington, New York, specializing in the development, manufacture, and distribution of therapeutic devices for surgical procedures. Founded in 2013, Abyrx offers a range of products, including resorbable hemostatic bone putties and applicator devices designed to stop bone bleeding and facilitate bone healing. The company's technology platforms not only support the re-approximation of bone surfaces but also enable the targeted delivery of drugs to bone. Abyrx's innovative solutions are utilized across various surgical fields, including orthopedic, cranial, maxillofacial, trauma, cardiothoracic, and spine surgeries, promoting efficient recovery for patients.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Natural Dental Implants AG, founded in 2006 and based in Berlin, Germany, specializes in the manufacture of non-surgical tooth replacement systems. The company focuses on creating innovative solutions for dental restoration, offering patented products that facilitate tooth replacement without the need for drilling or compromising healthy teeth. This minimally invasive approach aims to enhance patient comfort and preserve dental integrity, positioning Natural Dental Implants as a leader in the field of dental technology.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Sonetik AG is a Swiss company based in Bern that specializes in the development of hearing aids for individuals with hearing impairments. The company offers a range of digital hearing aids under the Sonetik GOhear brand, which includes models designed for various types of hearing loss, such as slightly sloping, steeply sloping, high frequency, and flat losses. Sonetik's approach utilizes preset configurations tailored to the most common patterns of hearing loss, allowing their specialists to match the appropriate hearing aid to the user's specific needs based on hearing test results. This method enables users to achieve similar benefits to those of custom-fitted hearing aids, but at a significantly lower cost, making hearing assistance more accessible. Sonetik AG operates as a subsidiary of Harvard International plc.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Aleva Neurotherapeutics SA is a Swiss company specializing in the development of advanced implantable deep brain stimulation (DBS) systems. Founded in 2008 and based in Lausanne, Aleva focuses on creating next-generation neurostimulation devices that utilize microelectromechanical systems (MEMS) technology. Its flagship product, directSTIM, features an array of directional microelectrodes that enable precise electrical stimulation, enhancing the efficacy of DBS therapy for conditions such as Parkinson's disease and essential tremor. In addition, Aleva has developed spiderSTIM, a diagnostic system that maps three-dimensional brain targets to optimize stimulation, and cortiSTIM, designed for cortical stimulation. The company is committed to maximizing the potential of its technology by launching a series of therapeutic products while carefully managing development risks. Aleva Neurotherapeutics is ISO13485 certified, underscoring its dedication to quality and safety in the medical device sector.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Vaximm is focused on developing active immunotherapies (vaccines) for patients suffering from cancer. Their initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Vaximm has shown impressive anti-tumor activity in various animal studies and will enter first human clinical trials in 2011.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Vivoryon Therapeutics AG is a clinical stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products for Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has completed Phase IIb clinical trials for Alzheimer's disease and is also being explored for cancer treatment. Additionally, Vivoryon is developing PQ1565, a small molecule inhibitor targeting glutaminyl-peptide cyclotransferase-like for cancer therapy, along with a monoclonal antibody aimed at enhancing the clearance of toxic pyroglutamate-Abeta. The company collaborates with various institutions, including the University Medical Center Schleswig-Holstein and Nordic Bioscience, to advance its clinical and research initiatives. Originally founded in 1997 as Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

ORTHOCON is a medical therapeutics company focused on developing innovative absorbable products specifically for orthopedic and spine surgeries. The company specializes in creating implantable products that effectively address bone bleeding, which is a common challenge in surgical procedures. Among its offerings is the HEMASORB Absorbable Bone Hemostat Matrix, a ready-to-use, biocompatible, water-resistant, and absorbable putty designed to halt bleeding when applied to damaged or cut bone. ORTHOCON's commitment to enhancing surgical outcomes is reflected in its development and manufacturing processes aimed at providing effective solutions for healthcare professionals in the field of orthopedics.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of novel anti-infectives aimed at women's health. Founded in 2008, Lumavita focuses on addressing infections that affect women, with key products including FemiFect, an antibiotic designed to treat vaginitis caused by various pathogens, and SPK-601, which targets human papilloma virus (HPV) and herpes simplex virus (HSV). The company operates as a subsidiary of Shogoo Pharmaceuticals KK and distributes its products through a network of distributors. Lumavita AG was previously known as Shogoo Pharmaceuticals, AG before rebranding in 2007.

BioVascular is a clinical stage biotechnology company focused on developing innovative products to address platelet-mediated cardiovascular diseases. Its lead product, saratin, is a recombinant polypeptide produced in yeast, which was originally discovered and licensed from Merck KGaA. The company is currently conducting human clinical trials for saratin, targeting applications in hemodialysis access grafts and peripheral artery grafts, with the aim of reducing intimal hyperplasia, a condition that can lead to graft failure. BioVascular's mission is to create novel therapeutics that address significant unmet medical needs in the treatment and prevention of vascular diseases, thereby improving patient outcomes in cardiovascular health.

Alpex Pharma SA is a pharmaceutical company based in Mezzovico-Vira, Switzerland, specializing in the research, development, and production of orally dispersible tablets, including effervescent and fast melt formulations. Established in 1983 and formerly known as Aesculapius Pharma SA, the company has developed proprietary technology that enhances the production of these unique tablet forms. Alpex Pharma operates a state-of-the-art facility spanning approximately 7,000 square meters, compliant with good manufacturing practices for both pharmaceutical and nutritional products. The company also offers a range of development services, including drug-excipient compatibility studies, analytical method development, and stability studies, positioning itself as a key player in the global market for fast melt and effervescent tablets.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Pevion Biotech is a biotechnology company that uses its proprietary technology platforms.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

ORTHOCON is a medical therapeutics company focused on developing innovative absorbable products specifically for orthopedic and spine surgeries. The company specializes in creating implantable products that effectively address bone bleeding, which is a common challenge in surgical procedures. Among its offerings is the HEMASORB Absorbable Bone Hemostat Matrix, a ready-to-use, biocompatible, water-resistant, and absorbable putty designed to halt bleeding when applied to damaged or cut bone. ORTHOCON's commitment to enhancing surgical outcomes is reflected in its development and manufacturing processes aimed at providing effective solutions for healthcare professionals in the field of orthopedics.

Tioga Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, founded in 2005. The company is dedicated to developing innovative therapies for the treatment of pruritus and gastrointestinal diseases. Its primary product is Asimadoline, an orally active kappa opioid receptor agonist designed to alleviate itching associated with atopic dermatitis. Additionally, Tioga is focused on treating gastrointestinal conditions, with Asimadoline also aimed at addressing irritable bowel syndrome and functional dyspepsia. This drug candidate is notable for its favorable safety profile, allowing for therapeutic benefits without the typical side effects associated with mu-opioid medications.

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of anti-infective products. The company primarily focuses on addressing gastrointestinal infections and related diseases that have limited treatment options. Its notable late-stage product candidates include fidaxomicin, an antibacterial drug designed for the treatment of Clostridium difficile-associated diarrhea, and Pruvel (prulifloxacin). In addition to these, Optimer's portfolio comprises CEM-101, OPT-822/OPT-821 combination therapy, and OPT-88. The company aims to create therapies that significantly improve patient outcomes and alleviate the burden of infectious diseases.

TargeGen, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2002. The company specializes in the discovery and development of small molecule kinase inhibitors aimed at addressing vascular leakage, vascular proliferation, and inflammation. TargeGen's products are designed for the treatment of various serious medical conditions, including heart attacks, cancer, and eye diseases. Specifically, their therapies target issues like vascular leakage, edema, unwanted growth of new blood vessels, pleural effusions, arthritis, pulmonary edema, transplant ischemia, acute respiratory distress syndrome, brain inflammation, and central nervous system disorders. The company has a particular focus on markets related to macular degeneration, diabetic macular edema, and diabetic retinopathy. In 2010, TargeGen was acquired by Sanofi Aventis.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Auxilium Pharmaceuticals, founded in 1999, specializes in the development and marketing of pharmaceutical products primarily aimed at urology and sexual health disorders. The company is committed to improving patient outcomes through the identification, development, and commercialization of innovative specialty biopharmaceuticals. Over the years, Auxilium has expanded its mission to address a broader range of unmet medical needs, focusing on creating novel treatment options that enhance the quality of life for patients dealing with various health challenges.

Eyetech Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for eye diseases. The company has made significant advancements in researching and treating wet age-related macular degeneration, a condition that leads to vision loss. Eyetech's work in this area has been recognized as a breakthrough in ophthalmic treatment. In 2012, Valeant Pharmaceuticals International acquired Eyetech for $22 million, furthering its mission to commercialize antiangiogenic drugs that aim to mitigate the impact of neovascular age-related macular degeneration on patients' vision.